CA2753876A1 - Methods for modulating circadian rhythms - Google Patents

Methods for modulating circadian rhythms Download PDF

Info

Publication number
CA2753876A1
CA2753876A1 CA2753876A CA2753876A CA2753876A1 CA 2753876 A1 CA2753876 A1 CA 2753876A1 CA 2753876 A CA2753876 A CA 2753876A CA 2753876 A CA2753876 A CA 2753876A CA 2753876 A1 CA2753876 A1 CA 2753876A1
Authority
CA
Canada
Prior art keywords
ampk
circadian
agonist
subject
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2753876A
Other languages
English (en)
French (fr)
Inventor
Ronald Evans
Katja A. Lamia
Reuben J. Shaw
Luciano Ditacchio
Satchidananda Panda
Uma M. Sachdeva
Craig B. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of CA2753876A1 publication Critical patent/CA2753876A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2864—Sleep disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2753876A 2009-03-20 2010-03-22 Methods for modulating circadian rhythms Abandoned CA2753876A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16222509P 2009-03-20 2009-03-20
US61/162,225 2009-03-20
PCT/US2010/028155 WO2010108179A1 (en) 2009-03-20 2010-03-22 Methods for modulating circadian rythms

Publications (1)

Publication Number Publication Date
CA2753876A1 true CA2753876A1 (en) 2010-09-23

Family

ID=42740034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2753876A Abandoned CA2753876A1 (en) 2009-03-20 2010-03-22 Methods for modulating circadian rhythms

Country Status (6)

Country Link
US (1) US20120264796A1 (enExample)
EP (1) EP2409152A4 (enExample)
JP (1) JP2012521364A (enExample)
AU (1) AU2010226417A1 (enExample)
CA (1) CA2753876A1 (enExample)
WO (1) WO2010108179A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2408906A4 (en) * 2009-03-20 2012-12-12 Salk Inst For Biological Studi METHODS FOR MODULATING METABOLIC AND CIRCADIAN RYTHMS
US20140186306A1 (en) * 2012-09-28 2014-07-03 Paul Ronald Plante Novel ampk agonist compositions and methods of use
US10572904B2 (en) 2017-03-29 2020-02-25 International Business Machines Corporation Micro circadian rhythms driven dynamic product offering adjustment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
US20070213295A1 (en) * 2006-01-16 2007-09-13 The Board Of Regents Of The University Of Texas System Methods and compositions for inducing torpor in a subject
TWI428767B (zh) * 2006-06-26 2014-03-01 Ibm 最佳化配置系統參數集之方法，程式及裝置
KR100766273B1 (ko) * 2006-10-23 2007-10-15 주식회사 녹십자 아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
JP2011507970A (ja) * 2007-12-28 2011-03-10 ザ ソーク インスティテュート フォー バイオロジカル スタディーズ 筋肉の能力および緊張を向上させるための方法

Also Published As

Publication number Publication date
EP2409152A1 (en) 2012-01-25
JP2012521364A (ja) 2012-09-13
AU2010226417A1 (en) 2011-10-13
EP2409152A4 (en) 2012-10-17
WO2010108179A1 (en) 2010-09-23
US20120264796A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
Narendra et al. The role of PINK1–Parkin in mitochondrial quality control
Forrestel et al. Chronomedicine and type 2 diabetes: shining some light on melatonin
Jagannath et al. The multiple roles of salt-inducible kinases in regulating physiology
US20120134985A1 (en) Methods for modulating metabolic and circadian rhythms
CN106459079B (zh) 青蒿素化合物及桥蛋白激动剂的医疗用途
US10526418B2 (en) Modulators of ACYL-COA lysocardiolipin acyltransferase 1 (ALCAT1) and uses thereof
CA2704648A1 (en) Methods and compositions for measuring wnt activation and for treating wnt-related cancers
Darshit et al. Activation of AKT1/GSK-3 β/β-Catenin–TRIM11/Survivin pathway by novel GSK-3 β inhibitor promotes neuron cell survival: study in differentiated SH-SY5Y cells in OGD model
CA2710764A1 (en) Methods for enhancing muscle performance and tone
Soeda et al. Inhibition of sphingomyelinase activity helps to prevent neuron death caused by ischemic stress
WO2016100385A2 (en) Compounds, compositions and methods for treating or preventing neurodegenerative disorders
US20120264796A1 (en) Methods for modulating circadian rhythms
US20110047633A1 (en) Control of Exocrine Pancreatic Function Using Bone Morphogenetic Proteins
Rozhkov et al. Inhibition of mTORC1 differentially affects ribosome biogenesis in rat soleus muscle at the early and later stages of hindlimb unloading
JPH11503519A (ja) インシュリンの擬似剤及び増強剤のアッセイ
EP1436623A1 (en) Modulation of tor
Thayer et al. PINK1-Parkin quality control mitophagy pathway in Parkinson’s disease
Stremming et al. Reduced Na+ K+-ATPase activity may reduce amino acid uptake in IUGR fetal sheep muscle despite unchanged ex vivo amino acid transporter activity
KR20100000387A (ko) 뼈 형성 촉진 기능을 가지는 퍼모파민 유도체를 함유한조성물
Mosca Regulation and Activation of Rankl Transcription in Primary Mouse Osteoblasts
Smith Novel Modes of Translational Regulation by eEF2K in the Peripheral Nervous System
Alarbi A Novel Role for the Tumor Suppressor P27 in Regulating Cancer Cell Metabolism and Hair Cortisol and Melatonin as Biomarkers of Our Circadian Rhythms
Reiter Translational control of gene expression in rat liver in relation to mammalian target of rapamycin signaling
Muaddi Phosphorylation of eukaryotic Initiation Factor 2-alpha at serine 51 is an important determinant of cell survival and adaptation to glucose deficiency

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160323